1. Interim Results for the six months
ended 31 October 2013
Parsortix development completed and
CE Mark awarded
Andrew Newland and Ian Griffiths
30 January 2014

2. Legal disclaimer
The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment
(without notice), verification and completeness.
This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly
or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided to recipients on
the basis that they keep confidential any information contained herein or otherwise made available, whether orally or in writing, in
connection with the Company. Neither this document or any part of this document nor any copy of it may be sent to or taken into
the United States of America, Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland, nor may it be
distributed to, directly or indirectly, to any US person (within the meaning of regulation S promulgated under the United States
Securities Act of 1933, (as amended) (the “US Securities Act”)). This document does not constitute an offer to buy or to subscribe
for, or the solicitation of an offer to buy or to subscribe for securities in the Company. To the extent this document is received or
used in jurisdictions outside the UK, any such recipient or user should inform themselves about and observe any applicable legal
requirements. Neither this document nor any part of this document should be copied or distributed by recipients and, in particular,
should not be distributed by any means, including electronic transmission, to persons with addresses in the United States of America
(or any of its territories or possessions) Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any
citizens, residents or nationals thereof, or to any corporation, partnership or other entity created or organised under the laws thereof
or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory
requirement. Any such distribution could result in violation of the laws of such countries.
This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to purchase
any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for any purpose
whatsoever on the information, representation or opinions.
This document should not be considered as the giving of investment advice by the Company or any of its shareholders, directors,
officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent
assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular,
any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis
and assumptions and each recipient should satisfy itself in relation to such matters.
Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the
accuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company accept any
responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising
in connection therewith.
Forward-Looking Statements
This presentation and the associated commentary contains certain forward-looking statements based on current expectations,
forecasts and assumptions that involve significant risks and uncertainties. These statements are based on information currently
available to the Company; and actual results could differ materially from those stated or implied, due to risks and uncertainties
associated with its business. Forward-looking statements include statements regarding expectations, beliefs, intentions or strategies
regarding the future and can be identified by forward-looking words such as “potential”, “target”, “anticipate”, “believe”, “could”,
“estimate”, “expect”, “intend”, “may”, “should”, “will”, and “would” or similar words. ANGLE assumes no obligation to update the
information included in this presentation, whether as a result of new information, future events or otherwise.
© ANGLE plc 2014
Page 2

3. Highlights
Completed the key development phase for the Parsortix system for
capturing circulating tumour cells (CTCs)
Balance sheet and medtech focus strengthened by sale of Geomerics to
ARM Holdings for up to £6.2m - £5.5m already received
CE Mark awarded for clinical use in Europe
Parsortix system well received by research partners, University of
Surrey Oncology Group and Cancer Research UK’s Paterson Institute
for Cancer Research
Now being evaluated by key opinion leaders in the fields of cancer
diagnosis and treatment
ANGLE now focused on securing US regulatory authorisation and
building the platform for widespread market adoption for the treatment
of cancer patients
© ANGLE plc 2014
Page 3

4. Financial Results for the six months ended 31 October 2013
H1 2014
H1 2013
£’000
£’000
Revenue
414
467
Investments portfolio gain
404
286
818
753
(1,374)
(1,126)
80
14
(476)
(359)
31Oct13
30Apr13
4,839
3,961
Trade and other receivables
530
454
Inventories
15
62
Cash
358
1,828
Property, plant and equipment
198
138
Intangible assets
1,099
1,080
Total assets
7,039
7,523
Statement of Comprehensive Income
Operating costs
Other income
Loss before tax
Statement of Financial Position
Investments
Comments
Increased investment
principally in Parsortix of
£1.1m up from £0.8m
•
•
Operating costs £0.8m
Capitalised expenditure £0.3m
Geomerics non-core
investment £4.8m
•
•
•
Sold after period end
Up to £6.2m cash
£5.5m received
Value of investments
increased by £0.9m
© ANGLE plc 2014
Page 4

5. Parsortix PR1 Machine successfully developed
© ANGLE plc 2014
Page 5

6. Parsortix PR1 System set for automated harvesting
© ANGLE plc 2014
Page 6

7. GEN3 cassette: captured HT-29 colorectal cancer cells
CK20 –green
CD45 – red
Nuclear stain - blue
HT29: CK20+ CD45WBC: CK20- CD45+
Spiked whole blood
Source: University of Surrey Oncology Department
© ANGLE plc 2014
Page 7

8. Key applications of Parsortix
Presence
− Microscope slide capture device enables the morphological examination of
captured cells with clear visibility of cell structure
− Step separation of 20µm allows easy visual sizing of cells
− Automated cell identification possible in situ within the cassette with a choice of
up to 7 reagents e.g. CK18+, DAPI+ and CD45-
Counting
− Microscope slide format enables the user to view and count captured cells
− Indication of disease status and progression
Harvesting
− Automated recovery of intact, undamaged, viable cells allows DNA analysis
− High level of cell purity
© ANGLE plc 2014
Page 8

9. Research partners
University of Surrey Oncology Department
Colorectal cancer patient validation
High CTC capture rate
Parsortix system demonstrated twice the sensitivity of currently accepted
clinical practice for CTC capture
Cancer Research UK’s Paterson Institute for Cancer Research
Positive evaluation. Key advantages identified:
− Epitope independent (does not use antibody capture)
− “Plug and play”
− Operationally versatile
− Biomarker compatible (harvested cells can be analysed)
Parsortix included in Paterson’s ongoing efforts to deliver personalised
medicine
© ANGLE plc 2014
Page 9

10. Sales platform
Sales priority to establish Parsortix in clinical practice
− working with cancer research centres to identify clinical applications
− securing positive clinical data demonstrating medical utility
− key opinion leader support
21 Parsortix PR1 systems deployed – 12 with key cancer groups
− 5 with research partners, Cancer Research UK’s Paterson Institute for Cancer
Research and the University of Surrey Oncology Group
− 3 leading cancer research centres in London, Cambridge and Germany
− 3 leading hospitals in London and Oxford
− 1 with a diagnostic company
Priority deployment of machines with key cancer groups
Beginning deployment of systems in support of research sales
Expect revenues to take time to develop and be modest initially
As each clinical application established expect sustained revenue growth
for that application
© ANGLE plc 2014
Page 10

11. Cambridge Parsortix laboratory
Partnership with Medical Research Council’s Cancer Unit at the
University of Cambridge to establish a Cambridge Parsortix laboratory
MRC Cancer Unit is a key opinion leader
MRC Cancer Unit research team, and the wider scientific community at
the University of Cambridge and Addenbrooke’s hospital, access to the
Parsortix system
Important recognition of the Parsortix system that the MRC Cancer Unit
has decided to invest in establishing a stand-alone Parsortix laboratory
within its facility
Core areas of investigation
− Bowel cancer including colorectal, pancreatic and oesophageal cancers
− Detection of cancer
− New drug compounds
− Gene mutation analysis and next-generation sequencing (NGS)
© ANGLE plc 2014
Page 11

12. Next Generation Sequencing
Third Scientific Adviser appointed
Dr Harold Swerdlow leading expert in next-generation sequencing (NGS)
Head of Research and Development for Wellcome Trust Sanger Institute
Invented core technology relating to NGS and commercialised this at
Solexa Ltd
Solexa was acquired by Illumina for US$600 million
Directs all next-generation DNA sequencing at Sanger
NGS premier technique in genetic and genomic analysis, fundamental to
personalised cancer treatment
Aligning Parsortix with NGS key commercial objective
© ANGLE plc 2014
Page 12

13. Objectives for current financial year
Strengthen balance sheet with sale of Geomerics - achieved
Place Parsortix system with key opinion leaders – in progress
3rd party validation of the Parsortix system - achieved
Select a manufacturing partner and establish quality control systems achieved
Plan for regulatory authorisation for the product to be used in the
clinical market - achieved
CE Mark authorisation for clinical sales in the Europe - achieved
Application to the FDA for authorisation for clinical sales in the United
States in Q1 2014
Market entry plan for Parsortix
© ANGLE plc 2014
Page 13

14. Contact details
Andrew Newland
ANGLE plc
3 Frederick Sanger Road
The Surrey Research Park
Guildford GU2 7YD
United Kingdom
Tel:
+44 1483 685830
Fax:
+44 1483 685836
Email:
andrew.newland@ANGLEplc.com
Website:
www.ANGLEplc.com
© ANGLE plc 2014
Page 14